Orgenesis Q1 EPS $(0.29) Down From $0.17 YoY, Sales $141.00K Miss $12.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Orgenesis (NASDAQ:ORGS) reported a significant decline in its Q1 earnings and sales. The company posted a loss of $(0.29) per share, a 270.59% decrease from $0.17 per share last year. Sales were $141.00K, missing the $12.00M estimate by 98.83% and down 98.00% from $7.04M last year.
May 21, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Orgenesis reported a significant decline in Q1 earnings and sales, with a loss of $(0.29) per share and sales of $141.00K, missing estimates by 98.83%. This is a major drop from last year's $0.17 EPS and $7.04M sales.
The significant decline in both earnings and sales, along with the large miss on analyst estimates, is likely to negatively impact the stock price in the short term. Investors may react strongly to the 270.59% decrease in EPS and the 98.83% miss on sales estimates.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100